CRTX Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Benzinga - Mentions: ASPC VRNS BLCO EAR ...

Stocks That Hit 52-Week Lows On Thursday

3 years ago - By: Benzinga - Mentions: LXRX TPTX GSK ABBV ...

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

3 years ago - By: Cortexyme, Inc.

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

3 years ago - By: Cortexyme, Inc.

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

3 years ago - By: Cortexyme, Inc.

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

3 years ago - By: Cortexyme, Inc.

Cortexyme Appoints June Bray to its Board of Directors

3 years ago - By: Cortexyme, Inc.

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

3 years ago - By: Cortexyme, Inc.

Cortexyme Successfully Completes Acquisition of Novosteo

3 years ago - By: Cortexyme, Inc.

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

3 years ago - By: Cortexyme, Inc.

Cortexyme Announces Agreement to Acquire Novosteo

4 years ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

4 years ago - By: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

4 years ago - By: The Rosen Law Firm, P.A.

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX

4 years ago - By: Cortexyme, Inc.

Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population

4 years ago - By: Rosen Law Firm, P.A.

ROSEN, A LEADING LAW FIRM, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - CRTX

4 years ago - By: InvestorPlace - Mentions: BGFV GOGO FUV BLNK ...

Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today

4 years ago - By: Cortexyme, Inc.

Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors

4 years ago - By: Cortexyme, Inc.

CORTEXYME INC (CRTX) Stock News

CRTX Latest News, Press Relases and Analysis

Stocks That Hit 52-Week Lows On Thursday

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme Appoints June Bray to its Board of Directors

Cortexyme Appoints Dr. Philip Low to Its Board of Directors

Cortexyme Successfully Completes Acquisition of Novosteo

Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

Cortexyme Announces Agreement to Acquire Novosteo

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX

Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population

ROSEN, A LEADING LAW FIRM, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - CRTX

Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today

Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors

Cortexyme to Present New GAIN Trial Data at AD/PD 2022